FDA approves Aerie drug sooner than expected – sales staff to grow
For Aerie Pharmaceuticals (Nasdaq: AERI) – a Duke University spinout that is in the process of building out its research and development team locally – Christmas did indeed come early.
Aerie announced Dec. 18 that the U.S. Food and Drug Administration has approved its eye drop Rhopressa for the treatment of glaucoma and hypertension i n the eyes, two months ahead of its scheduled PDUFA date. The company also said it has plans to hire a sprawling field sales force.
"We are proud of the work we…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Jennifer Henderson Source Type: news
More News: American Health | Eyes | Food and Drug Administration (FDA) | Glaucoma | Health Management | Hypertension